Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs
"We are benefiting from very significant growth of the GLP-1 class," said Conterno, president of Lilly Diabetes and Lilly USA, at the UBS Global Healthcare Conference in New York. "And in fact, as we see additional competitors, they are further fueling ...
Is Eli Lilly (LLY) a Great Dividend Play?
Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid ...
Eli Lilly posts quarterly loss, to take animal health unit public
Eli Lilly posted a second-quarter loss on Tuesday, hurt by acquisition-related charges of $1.62 billion. Continue Reading Below. The company incurred a net loss of $259.9 million, or 25 cents per share, in the second quarter, compared with a profit of ...